FK-506  more patients discontinuing treatment due to peripheral edema with A monotherapy than with T/A SPC. DBP and achieving the 4-hour BP goal of 3 CONCLUSIONS mm Hg than A monotherapy. This conms results from the factorial design stu in which patients treated with T/A achieved a signi antly higher 4-hour BP goal ratepared with those treated with A In this -week stu initial treatment with T/A SPC was an effective and well-tolerated treatment in this selected group of hypertensive patients with diabetes. Clinical evidence suggests that such abination is . 5 bene ial to decrease CV risk in this type of added-risk The tolerability analysis showed thatparable numbers of patients in the treatment groups expe-rienced adverse even and the majority of these were mild or moderate.

With noparator placebo a the reported adverse events should not be ig-nored; howev  Dioscin these adverse event rates were sim-ilar to those previously observed for the T/Abi-nation. 2 Patient retention in the study was hig similar to that of an earlier study of this treatmentbinatio suggesting a high treatment adherence. 2 The mostmon adverse events are all known adverse events for such kind of treatments. 4 Headache is-mon in patients with hypertensi and its incidence was previously reported to be lower with telmisartan than with placebo. 4 The onset of peripheral edema was apparently related to the use of amlodipine and dose depende and the overall incidence was numer-ically decreased when amlodipine was used inbi-nation with telmisartan. These dings were in line with results suggesting low rates of peripheral edema when an ARB such as  Zoledronate 118072-93-8 telmisartan isbined with patients and may be considered a preferred treatment option in patients with metabolic disorders such as diabet and obesity.

ACKNOWLEDGMENTS This study was sponsored by Boehringer Ingelheim In-ternational GmbH. Writing and editorial assistance was provided by Emma Fulk P of PAREX which was contracted by Boehringer Ingelheim Inter-national GmbH for these services. The  buy ITMN-191 authors meet criteria for authorship as rmended by the Inter-nationalmittee of Medical Journal Edito were fully responsible for all content and editorial decisions and were involved in all stages of manuscript develop-ment except Dr. Littlejo who died during the devel-opment of this manuscript and was not able to approve the al draft. Dr. Ting is the study statistician and provided the analysis of the data. Ms. Kobe is the trial clinical monitor. All authors contributed equally to the development of the manuscript. The authors received nopensation related to the development of the manuscript.

Volume 4 Number A.M. Sharma CONFLICTS OF INTEREST Dr. Sharma has received consulting and speaking hon-oraria and research funding from Boehringer Ingel-heim. Dr. Bakris has received grants and support from Forest La Novart Medtron and Relapysa; has been a consultant for Take Abbo CV Johnson & Johns Servi Eli Lil and the US Food and Drug Administration; has participated in speaker bu-reaus for Takeda and Novartis; served on advisory boards for the National Kidney Foundation and the American Society of  anatomy Hypertension; and is Editor of the American Journal of Nephrology and Associate Editor of Diabetes Ca Nephrology Dialysis and Trans-plant  Dr. Littlejohn.